Deals > All

East Germany North Germany South Germany West Germany Austria Germany Switzerland [ # 12 & 35 ]

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3745 | Ordered by Date (descending)
1 2 3 ... 36 37 38

Deal: Collaboration or Financing	Date
Mologen–Signal Iduna: investment, 201512 existing investor Deutscher Ring Krankenversicherung holding estimated 6% in Mologen	2015-12-31
Boehringer–Polyphor: drug discovery, 201512 collab existent to identify + optimise drug candidates using macrocycle platform	2015-12-22
Convergence Pharmaceuticals–Evotec: investment, 201512 acquisition of 51% of shares of Panion Ltd	2015-12-09
Bridgepoint–Kohlberg Kravis Roberts: investment, 201512 acquisition €na of LGC by KKR from Bridgepoint	2015-12-08
TiGenix–Cormorant Asset Management: investment, 201511 private placement totalling €8.7m incl €4.7m to Cormorant Global Healthcare	2015-11-25
TiGenix–SEVERAL: investment, 201511 private placement €8.7m with 9.1m new shares €0.95/share to Cormorant + European institutional investors	2015-11-25
Omeicos–Germany (govt): grant, 201511– BMBF research grant €1.7m	2015-11-02
MTIP MedTech Innovation Partners–SEVERAL: investment, 201511–201604 1st closing CHF30m of 1st MTIP Fund	2015-11-01
Tusk Therapeutics–SEVERAL: investment, 201511 financing round Series A €30m	2015-11-01
Arvinas–SEVERAL: investment, 201510 financing round Series B $41.6m led by RA Capital Management	2015-10-21
Science 37–Novartis: investment, 201510 financing round Series A totalling $6.5m co-led by Lux Capital + dRx Capital	2015-10-20
Science 37–SEVERAL: investment, 201510 financing round Series A $6.5m co-led by Lux Capital + dRx Capital	2015-10-20
Zavante Therapeutics–SEVERAL: investment, 201510 seed financing round	2015-10-09
Roche–Arvinas: protein degradation drugs, 201510– strategic license multi-year for PROTAC technology to Genentech	2015-10-01
Taisho–Polyphor: drug discovery, 201509– collab €na identification of drug candidates using macrocycle platform	2015-09-17
Baxalta–Novimmune: therapeutic antibodies, 201509– collab RnD €na bispecific antibodies for hemophilia A	2015-09-02
Intellia Therapeutics–Novartis: investment, 201509 financing round Series B totalling $70m led by OrbiMed + incl co-investor Novartis	2015-09-01
Intellia Therapeutics–SEVERAL: investment, 201509 financing round Series B $70m led by OrbiMed HealthCare Fund Management	2015-09-01
Protembis–SEVERAL: investment, 201507 seed financing round 7-digit € incl Innovationsstarter Fonds + Geratherm + angel investors	2015-07-28
Accurate Mass Scientific–CovalX: mass spectrometry, 201507– collab AMS new Australian distributor of CovalX High-Mass systems + CRO analytics services	2015-07-15
AdvanDx–OpGen: investment, 201507 merger acquisition by AdvanDx for 682k shares of OpGen common stock	2015-07-14
ViraTherapeutics–Austria (govt): investment, 201506 financing round Series A 1st closing totalling €3.6m incl co-investor aws	2015-06-23
ViraTherapeutics–Boehringer: investment, 201506 financing round Series A 1st closing totalling €3.6m co-led by BIVF + EMBL Ventures	2015-06-23
ViraTherapeutics–EMBL: investment, 201506 financing round Series A 1st closing totalling €3.6m co-led by BIVF + EMBL Ventures	2015-06-23
Juno Therapeutics–Editas Medicine: cancer immunotherapy, 201505– strategic alliance to develop CAR-T + engineered TCR therapies	2015-05-27
Arcus Biosciences–Novartis: investment, 201505 financing round Series A totalling $49.7m incl co-investor Novartis	2015-05-01
Arcus Biosciences–SEVERAL: investment, 201505 financing round Series A $49.7m incl F&F + Column Group + Foresite Capital + Novartis + Celgene	2015-05-01
Cyclenium–Haplogen: virostatic agents, 201505– collab drug discovery small molecule macroycle inhibitors using CMRT technology	2015-05-01
Blueberry Therapeutics–SEVERAL: investment, 201504 financing round $1.75m from UK + Swiss investors	2015-04-08
Caribou Biosciences–SEVERAL: investment, 201504 financing round Series A $11m incl Fidelity Biosciences + Novartis + Mission Bay Capital et al	2015-04-02
Macrolide–Bertarelli Group: investment, 201503 financing round Series A totalling $22m inc co-lead investor Gurnet Point Capital	2015-03-04
Macrolide–GSK: investment, 201503 financing round Series A totalling $22m inc co-lead investor SROne	2015-03-04
Macrolide–Novartis: investment, 201503 financing round Series A totalling $22m inc co-lead investor Novartis Venture Fund	2015-03-04
Macrolide–Roche: investment, 201503 financing round Series A totalling $22m inc co-lead investor Roche Ventures	2015-03-04
Macrolide–SEVERAL: investment, 201503 financing round Series A $22m led by NVF + Gurnet Point + Roche Ventures + SR One	2015-03-04
OpGen–SEVERAL: investment, 201503–201505 IPO $17.1m+$2.565m with 2.85m+427.5k units consisting of 1 share + 1 warrant at $6/unit	2015-03-03
Genenta Science–SEVERAL: investment, 201503 financing round Series A €10m	2015-03-01
Canbex Therapeutics–Ipsen: investment, 201502 Ipsen pays €6m upfront for option to acquire Canbex upon Ph2a completion of VSN16R in MS spasticity	2015-02-24
R2R Biofluidics project–EU (govt): grant, 201502–201901 H2020 grant €6.4m out of total budget of €7.9m	2015-02-01
ASPEC Technologies–CovalX: mass spectrometry, 201501 collab existent ASPEC is distributor of CovalX High-Mass systems in China	2015-01-15
Boehringer–Vanderbilt Univ: Ras inhibitors, 201703– collab expansion RnD small-molecule KRAS inhibitors for cancer	2015-01-13
Aquila Biolabs–SEVERAL: investment, 2015 seed financing round 7-digit €	2015-01-01
Atomwise–SEVERAL: investment, 2015 seed financing round incl Y Combinator + Khosla Ventures + DJF	2015-01-01
Biocentric–Hain Lifescience: investment, 2015 acquisition of Biocentric by Hain	2015-01-01
GreenBone–SEVERAL: investment, 2015 seed financing round €3m from ZernikeMeta Ventures + Italian Angels for Growth + private investors	2015-01-01
IFM Therapeutics–Atlas Venture: investment, 2015 seed funding by Atlas Venture	2015-01-01
Jecure Therapeutics–Versant Ventures: investment, 2015 seed financing from founding investor Versant Ventures	2015-01-01
KBI BioPharma–JSR Corp: investment, 2015 acquisition of KBI BioPharma Inc by JSR Corp	2015-01-01
Kurma–SEVERAL: investment, 2015 final closing €35m of Kurma Diagnostics Fund (KDx)	2015-01-01
Novartis–Fraunhofer: cell therapy production, 201501– collab developm of production capacity for Kymriah in Europe at Fraunhofer IZI	2015-01-01
Novartis–Fraunhofer: cell therapy production, 201808– service supply production of Kymriah in Europe by Fraunhofer IZI	2015-01-01
Numares–SHS: investment, 2015 existent SHS Gesellschaft für Beteiligungsmanagement is main shareholder	2015-01-01
Roche–4D Molecular Therapeutics: gene delivery technology, 2015– collab research	2015-01-01
VIB–Lipotype: mass spectrometry services, 2015– collab supply of shotgun lipidomics services by Lipotype to researchers at VIB	2015-01-01
ViraTherapeutics–Austria (govt): investment, 2015c financing €1.6m from FFG + aws seed financing programme	2015-01-01
Pieris–Ally Bridge Group: investment, 201412 private placement totalling $13.56m incl investor ABG	2014-12-18
Annexon–Clarus Ventures: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Clarus Ventures	2014-12-15
Annexon–Novartis: investment, 201412 financing round Series A-1 totaliing $34m incl lead investor NVF	2014-12-15
Annexon–Satter Investment Management: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Satter	2014-12-15
Annexon–SEVERAL: investment, 201412 financing round Series A-1 $34m led by NVF + incl Satter Investment + Clarus Ventures	2014-12-15
Tiziana–Novimmune: therapeutic antibody, 201412– license to foralumab (NI-0401) to Tiziana	2014-12-01
Pepperprint–Sciomics: microarray technology, 201411– collab distribution + marketing for antibody characterisation + biomarker discovery	2014-11-18
Roche–NewLink Genetics: cancer drugs, 201410– collab drug discovery IDO/TDO inhibitors with Genentech	2014-10-16
Ipsen–MHH: rec botulinum neurotoxin, 201409– collab RnD with Thomas Binz at Institute for Physiological Chemistry at MHH	2014-09-01
i3 Membrane–SEVERAL: investment, 201408 investment by HTGF + Innovationsstarter Fonds Hamburg	2014-08-01
Geisinger–Indivumed: tissue bank, 201407– collab to create cancer research biobanks at Geisinger + Indivumed	2014-07-15
AbbVie–Apogenix: TRAIL receptor agonists, 201407 aquisition of ww rights to all TRAIL receptor agonists of Apogenix by AbbVie	2014-07-01
B Braun–CeGaT: personalised medicine, 201406 collab establishment of B Braun CeGaT LLC in Pennsylvania	2014-06-01
Novartis–Ophthotech: pegpleranib, 201405– excl license + commercialisation agreem outside of US	2014-05-01
Essen BioScience–SFW Capital Partners: investment, 201405 strategic investment in Essen BioScience by SFW	2014-04-15
Roche–Oryzon Genomics: LSD1 inhibitors, 201605–201707 collab extension developm of ORY-1001 TERMINATED 7/17	2014-04-07
Synaffix–Aravis: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital	2014-02-18
Synaffix–BioGeneration Ventures: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital	2014-02-18
Synaffix–BOM Capital: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital	2014-02-18
Synaffix–Merck (DE): investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital	2014-02-18
CeeTox–Cyprotex: investment, 201401 acquisition of assets + business of CeeTox by Cyprotex	2014-01-01
Electrochaea–SEVERAL: investment, 2014 financing round Series A	2014-01-01
Horizon Discovery–ERS Genomics: CRISPR technology, 2014– license ww non-excl to Horizon	2014-01-01
Mestex–SEVERAL: investment, 2014 1st financing round	2014-01-01
Provecs–Cevec: rec protein production technology, 2014– license to CAP GT technology for cancer immunotherapy	2014-01-01
Rebiotix–SEVERAL: investment, 2014 financing round Series B $25m	2014-01-01
Sirion Biotech–LaVoieHealthScience: public relations, 2014– supply service US PR/IR	2014-01-01
Tusk Therapeutics–Droia Ventures: investment, 201809 existent majority shareholder + founding investor Droia Oncology Ventures	2014-01-01
Sirion Biotech–Cevec: cell lines, 201312– license €na to CAP cell lines for expression of AAV vectors	2013-12-19
Eloxx Pharmaceuticals–SEVERAL: investment, 201311 initial closing of 1st financing round with Roche + Pontifax	2013-11-21
Mission Therapeutics–Roche: investment, 201311 financing round Series B totalling £20m incl existing investor Roche Venture Fund	2013-11-18
Polymedco–Epigenomics: molecular diagnostics, 201310– collab joint commercialisation of Epi proColon test in North America	2013-10-02
Gardner Denver–Kohlberg Kravis Roberts: investment, 201307 acquisition 100% for $3.9b incl assumption of debt	2013-07-16
Bruker–3M: MALDI Imaging, 201609– license expansion excl to technique for performing MS analysis on FFPE tissue for pathology	2013-06-04
Allecra Therapeutics–EMBL: investment, 201304 financing round Series A totalling €15m incl co-investor EMBL Ventures	2013-04-18
Allecra Therapeutics–Forbion: investment, 201304 financing round Series A totalling €15m incl co-lead investor Forbion	2013-04-18
Allecra Therapeutics–LCF Rothschild: investment, 201304 financing round Series A totalling €15m incl co-lead investor EdRIP	2013-04-18
ABF–Genedata: bioinformatics, 2013– supply use of Genedata Selector by AB Enzymes for strain genome data management	2013-01-01
BioNTech–MAB Discovery: antibody technology, 2013– collab mAb generation using technology of MAB Discovery	2013-01-01
Boehringer–Qiagen: molecular companion diagnostics, 2013 collab existent incl therascreen EGRF RGQ PCR Kit for Giotrif	2013-01-01
Kaiser Optical Systems–Endress+Hauser: investment, 2013 acquisition by Endress+Hauser	2013-01-01
PlasmidFactory–Sirion Biotech: gene delivery technology, 201212– collab pronotion of AAV vectors for preclinical ersearch	2012-12-04
Roche–AC Immune: therapeutic antibodies, 201206– license excl for anti-Tau program for Alzheimer’s disease to Genentech	2012-06-01
B Braun–CeGaT: personalised medicine, 201201– collab strategic partnership to expand + internationalise CeGaT’s business	2012-01-31
Bayer–X-Chem: small-molecule drug discovery, 2012– collab research using DEX technology	2012-01-01

1 2 3 ... 36 37 38

Picture [iito] No Content Marketing 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

» top